Prolonged mycophenolate mofetil and truncated cyclosporine postgrafting immunosuppression to reduce life-threatening GVHD [graft-versus-host disease] after unrelated donor peripheral blood stem cell transplantation using nonmyeloablative conditioning for patients with hematologic malignancies and renal cell carcinoma - a multi-center trial

Trial Profile

Prolonged mycophenolate mofetil and truncated cyclosporine postgrafting immunosuppression to reduce life-threatening GVHD [graft-versus-host disease] after unrelated donor peripheral blood stem cell transplantation using nonmyeloablative conditioning for patients with hematologic malignancies and renal cell carcinoma - a multi-center trial

Active, no longer recruiting
Phase of Trial: Phase I/II

Latest Information Update: 03 Mar 2017

At a glance

  • Drugs Ciclosporin (Primary) ; Mycophenolate mofetil (Primary) ; Fludarabine
  • Indications Acute lymphoblastic leukaemia; Acute myeloid leukaemia; Chronic lymphocytic leukaemia; Chronic myeloid leukaemia; Graft-versus-host disease; Haematological malignancies; Hodgkin's disease; Multiple myeloma; Myelodysplastic syndromes; Myeloproliferative disorders; Non-Hodgkin's lymphoma; Renal cancer
  • Focus Therapeutic Use
  • Most Recent Events

    • 03 Jul 2013 New source identified and integrated (German Clinical Trials Register; DRKS00004002).
    • 08 Jun 2012 Additional lead trial centre added as reported by ClinicalTrials.gov record.
    • 16 Nov 2011 Planned End Date changed from 1 Jan 2005 to 1 Jan 2006 as reported by ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top